Metformine Hydrochloride Inventia (Metformin Hydrochloride)

Metformin reduces hepatic glucose production by inhibiting mitochondrial complex I, which decreases gluconeogenesis. It also enhances peripheral insulin sensitivity, promoting glucose uptake in muscle and adipose tissue through increased GLUT4 translocation, thereby lowering circulating glucose without stimulating insulin release.

The dosage of Metformine Hydrochloride Inventia is individualized. A qualified prescriber determines the appropriate dose based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety of metformin in pregnancy and lactation should be evaluated by a healthcare professional. While some guidelines allow its use when benefits outweigh risks, clinicians must assess each case. Breastfeeding mothers should discuss potential exposure with their physician before continuing therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metformin is a first‑line biguanide distinguished by its ability to lower glucose without causing weight gain and with a low risk of hypoglycemia when used alone. Compared with sulfonylureas or meglitinides, it does not stimulate insulin secretion, making it suitable for patients where insulin resistance is predominant.

Metformine Hydrochloride Inventia should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients must follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablets unless directed.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, dehydration, or excessive alcohol intake. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing, or abdominal pain develop.

Metformine Hydrochloride Inventia is contraindicated in patients with known hypersensitivity to metformin, severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with significant hepatic disease. Clinicians should evaluate each patient’s medical history before initiating therapy.